Raloxifene and Risk for Stroke Based on the Framingham Stroke Risk Score

American Journal of Medicine

Volumn 122, Issue 8, 2009, Pages 754-761

  Barrett Connor, Elizabeth ^a   Cox, David A ^b   Song, Jingli ^b   Mitlak, Bruce ^b   Mosca, Lori ^c   Grady, Deborah ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c NewYork Presbyterian Hospital   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Framingham; Raloxifene; SERM; Stroke

Indexed keywords

PLACEBO; RALOXIFENE;

AGED; ARTICLE; BREAST CANCER; CORONARY RISK; FEMALE; FRAMINGHAM STROKE RISK SCORE; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; STROKE; VALIDATION STUDY; VERTEBRA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SPINAL FRACTURES; STROKE;

EID: 67651232250     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.01.033     Document Type: Article

References (19)

1. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
2. Cummings S., Eckert S., Krueger K., et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281 (1999) 2189-2197
3. Barrett-Connor E., Mosca L., Collins P., et al., Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137
4. Grady D., Cauley J.A., Geiger M.J., et al., Raloxifene Use for The Heart Trial Investigators. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 100 (2008) 854-861
5. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 (2002) 847-857
6. Mosca L., Grady D., Barrett-Connor E., et al. Effect of raloxifene on stroke and venous thromboembolism: a randomized controlled trial in postmenopausal women with or at increased risk of coronary heart disease. Stroke 40 (2009) 147-155
7. Petty G.W., Brown Jr. R.D., Whisnant J.P., et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 50 (1998) 208-216
8. Sacco R.L., Shi T., Zamanillo M.C., and Kargman D.E. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 44 (1994) 626-634
9. Hier D.B., Foulkes M.A., Swiontoniowski M., et al. Stroke recurrence within 2 years after ischemic infarction. Stroke 22 (1991) 155-161
10. Wolf P.A., D'Agostino R.B., Belanger A.J., and Kannel W.B. Probability of stroke: a risk profile from the Framingham Study. Stroke 22 (1991) 312-318
11. D'Agostino R.B., Wolf P.A., Belanger A.J., and Kannel W.B. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 25 (1994) 40-43
12. Goldstein L.B., Adams R., Alberts M.J., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 1583-1633
13. Cappuccio F.P., Oakeshott P., Strazzullo P., and Kerry S.M. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ 325 7375 (2002) 1271-1276
14. Vokó Z., Hollander M., Koudstaal P.J., et al. How do American stroke risk functions perform in a Western European population?. Neuroepidemiology 23 (2004) 247-253
15. Cauley J.A., Norton L., Lippman M.E., et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65 (2001) 125-134
16. Mosca L., Barrett-Connor E., Wenger N., et al. Design and methods of the Raloxifene Use For the Heart (RUTH) Study. Am J Cardiol 88 (2001) 392-395
17. Rockhill B., Byrne C., Rosner B., et al. Breast cancer risk prediction with a log-incidence model: evaluation of accuracy. J Clin Epidemiol 56 (2003) 856-861
18. Eichler K., Puhan M.A., Steurer J., and Bachmann L.M. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 153 (2007) 722-731 731.e1-8
19. O'Regan C., Wu P., Arora P., et al. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 121 (2008) 24-33